prasugrel related Press Releases
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel TOKYO and INDIANAPOLIS, Ind., May 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- A new substudy from 1,466
... Read more...European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI TOKYO and INDIANAPOLIS, Feb. 23 /PRNewswire-FirstCall/ -- Heart patients with acute
... Read more...Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee TOKYO and INDIANAPOLIS, Feb. 3 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration Cardiovascular and
... Read more...Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP)
Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) TOKYO and INDIANAPOLIS, Dec 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --
... Read more...FDA Continues to Review Prasugrel New Drug Application
FDA Continues to Review Prasugrel New Drug Application TOKYO and INDIANAPOLIS, Sept. 26 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited, (TSE: 4568) and Eli Lilly and Company (NYSE: LLY)... Read more...
FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel Companies confirm the start of TRILOGY ACS clinical trial to study Prasugrel against Clopidogrel in... Read more...
FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel Investigational antiplatelet agent submitted for treatment of patients with acute coronary syndrome being managed with... Read more...
Daiichi Sankyo, Lilly Submit NDA for Investigational Antiplatelet Drug, Prasugrel, to FDA
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration If Approved for Marketing in the United States, Trade Name... Read more...
PRESS RELEASE: In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel
In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack Investigational compound reduces risk of major cardiovascular events by 19... Read more...
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
